BR112012029280A2 - variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão - Google Patents
variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusãoInfo
- Publication number
- BR112012029280A2 BR112012029280A2 BR112012029280A BR112012029280A BR112012029280A2 BR 112012029280 A2 BR112012029280 A2 BR 112012029280A2 BR 112012029280 A BR112012029280 A BR 112012029280A BR 112012029280 A BR112012029280 A BR 112012029280A BR 112012029280 A2 BR112012029280 A2 BR 112012029280A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- immunoglobulin
- multispecific ligand
- variant
- serum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34651910P | 2010-05-20 | 2010-05-20 | |
| PCT/EP2011/058298 WO2011144751A1 (en) | 2010-05-20 | 2011-05-20 | Improved anti-serum albumin binding variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012029280A2 true BR112012029280A2 (pt) | 2016-11-29 |
Family
ID=44352234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012029280A BR112012029280A2 (pt) | 2010-05-20 | 2011-05-20 | variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9040668B2 (https=) |
| EP (1) | EP2571900A1 (https=) |
| JP (1) | JP2013529080A (https=) |
| KR (1) | KR20130109977A (https=) |
| CN (1) | CN103003303A (https=) |
| AU (1) | AU2011254559B2 (https=) |
| BR (1) | BR112012029280A2 (https=) |
| CA (1) | CA2799633A1 (https=) |
| EA (1) | EA201291009A1 (https=) |
| IL (1) | IL222802A0 (https=) |
| MX (1) | MX2012013406A (https=) |
| SG (1) | SG185437A1 (https=) |
| WO (1) | WO2011144751A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| LT3374392T (lt) * | 2015-11-13 | 2022-01-25 | Ablynx Nv | Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2025021183A1 (zh) * | 2023-07-27 | 2025-01-30 | 上海复宏汉霖生物医药有限公司 | 编码促肾上腺皮质激素的多核苷酸及其相关组合物和方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| ATE479760T1 (de) | 2004-03-24 | 2010-09-15 | Domantis Ltd | Universelles signalpeptid gas1 |
| TW200607523A (en) | 2004-06-01 | 2006-03-01 | Domantis Ltd | Drug compositions, fusions and conjugates |
| CN101128487B (zh) | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
| US20100047171A1 (en) | 2006-01-24 | 2010-02-25 | Roland Beckmann | Fusion Proteins That Contain Natural Junctions |
| JP2010528647A (ja) | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| CA2688433A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| US20090148905A1 (en) | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
| AU2010215479B2 (en) | 2009-02-19 | 2015-01-22 | Glaxo Group Limited | Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists |
| EP2398825B1 (en) * | 2009-02-19 | 2017-10-25 | Glaxo Group Limited | Single variable domain against serum albumin |
| EP3656788A3 (en) * | 2009-02-19 | 2020-07-29 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| CN104127880A (zh) * | 2009-03-27 | 2014-11-05 | 葛兰素集团有限公司 | 药用融合体和缀合物 |
| JP2012532619A (ja) * | 2009-07-16 | 2012-12-20 | グラクソ グループ リミテッド | Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法 |
| CN104147611A (zh) | 2009-09-30 | 2014-11-19 | 葛兰素集团有限公司 | 具有延长的半衰期的药物融合体和缀合物 |
-
2011
- 2011-05-20 EP EP11720310A patent/EP2571900A1/en not_active Withdrawn
- 2011-05-20 AU AU2011254559A patent/AU2011254559B2/en not_active Ceased
- 2011-05-20 KR KR1020127033268A patent/KR20130109977A/ko not_active Withdrawn
- 2011-05-20 JP JP2013510643A patent/JP2013529080A/ja active Pending
- 2011-05-20 EA EA201291009A patent/EA201291009A1/ru unknown
- 2011-05-20 US US13/698,794 patent/US9040668B2/en not_active Expired - Fee Related
- 2011-05-20 MX MX2012013406A patent/MX2012013406A/es not_active Application Discontinuation
- 2011-05-20 BR BR112012029280A patent/BR112012029280A2/pt not_active IP Right Cessation
- 2011-05-20 WO PCT/EP2011/058298 patent/WO2011144751A1/en not_active Ceased
- 2011-05-20 CA CA2799633A patent/CA2799633A1/en not_active Abandoned
- 2011-05-20 CN CN2011800351661A patent/CN103003303A/zh active Pending
- 2011-05-20 SG SG2012081683A patent/SG185437A1/en unknown
-
2012
- 2012-11-01 IL IL222802A patent/IL222802A0/en unknown
-
2015
- 2015-04-21 US US14/691,913 patent/US20150284454A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103003303A (zh) | 2013-03-27 |
| EA201291009A1 (ru) | 2013-05-30 |
| SG185437A1 (en) | 2012-12-28 |
| US20150284454A1 (en) | 2015-10-08 |
| CA2799633A1 (en) | 2011-11-24 |
| IL222802A0 (en) | 2012-12-31 |
| EP2571900A1 (en) | 2013-03-27 |
| WO2011144751A1 (en) | 2011-11-24 |
| MX2012013406A (es) | 2012-12-10 |
| AU2011254559A1 (en) | 2013-01-17 |
| US20130129746A1 (en) | 2013-05-23 |
| JP2013529080A (ja) | 2013-07-18 |
| US9040668B2 (en) | 2015-05-26 |
| KR20130109977A (ko) | 2013-10-08 |
| AU2011254559B2 (en) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012029280A2 (pt) | variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão | |
| WO2013170272A3 (en) | Site-specific labeling and targeted delivery of proteins for the treatment of cancer | |
| EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
| MX355255B (es) | Variantes de fc y métodos para su producción. | |
| AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| MX2012012119A (es) | Produccion de proteinas heteromultimericas. | |
| WO2013092983A3 (en) | Enzymatic conjugation of polypeptides | |
| AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| CY1117236T1 (el) | Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 | |
| CA2796722C (en) | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | |
| BR112016014293A2 (pt) | região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune | |
| EP4406612A8 (en) | Anti-cd70 antibody drug conjugates | |
| EA201291098A1 (ru) | Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ | |
| PH12014502179A1 (en) | Ang2-binding molecules | |
| EA201490768A1 (ru) | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера | |
| IN2012DN00640A (https=) | ||
| UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
| EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
| BR112015002765A2 (pt) | proteína de fusão, polinucleotídeo, vetor, célula hospedeira, métodos para produzir a proteína de fusão, de tratamento de uma doença em um indivíduo e para ativação seletiva in vitro ou in vivo de células reguladoras, composição farmacêutica, uso da proteína de fusão e invenção. | |
| BR112014000263A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| MX387941B (es) | Biblioteca de moleculas de union dependientes de la concentracion ionica. | |
| BR112012031843A2 (pt) | molécula de peptídeo, molécula de ácido nucleico, vetor, célula hospedeira, método de produção de peptídeo, composição, método de produção da composição, método de detecção do comportamento de internalização do peptídeo, composição farmacêutica, uso do peptídeo, método para a prevenção e/ou tratamento e kit de partes | |
| UA115906C2 (uk) | Fc-ФРАГМЕНТ ІМУНОГЛОБУЛІНУ IgG4, ЯКИЙ МАЄ МОДИФІКОВАНУ ШАРНІРНУ ДІЛЯНКУ | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/18 (2006.01), A61K 47/68 (2017.01), C07K 1 |